Atherosclerosis Clinical Trials

Find Atherosclerosis Clinical Trials Near You

Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Atherosclerotic Stenosis Patients: A Multicenter Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Drug, Procedure
Study Type: Observational
SUMMARY

The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age between 18 and 80 years

• Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD)

• Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \[NIHSS\] score ≤ 4 points)

• Right-handed and able to cooperate in neuropsychological tests

• At least 14 days post-onset of cerebral infarction or TIA

• Signed informed consent

Locations
Other Locations
China
Anhui Medical University
RECRUITING
Hefei
Contact Information
Primary
Kai Wang, PhD
wangkai1964@126.com
+86-0551-62922263
Backup
Qiang Wei, PhD
qiangwei_914@126.com
+8618134516380
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 100
Treatments
Surgery Group
Symptomatic intracranial stenosis patients who receive endovascular therapy combined with standard medical treatment
Medical group
Symptomatic intracranial stenosis patients who receive standard medical treatment without endovascular therapy
Related Therapeutic Areas
Sponsors
Leads: Anhui Medical University

This content was sourced from clinicaltrials.gov